Durham 의료기술 스타트업 Xilis가 $70M을 모금했습니다. 후원자 중 Google Ventures, Duke Angels

게시 날짜:

자일리스, a startup founded by two professors at Duke University focusing on technology to boost precision health and oncology, has landed $70 million in new funding with Google Ventures among the backers.

The two-year-old company had previously raised close to $5 million.

“Our vision is to transform cancer care in diagnostics and reshape drug development by providing a technology for rapid therapeutic profiling,” said Xiling Shen, founder and CEO of Xilis, in Thursday’s announcement.. “The support provided by these world-class investors is an important milestone for our journey to transform cancer care and dramatically improve patient survival by enabling personalized precision oncology and bringing transformative medicines to patients faster and with higher success rates.”

Xilis는 암 환자를 위한 정밀 치료법 전달을 지원할 뿐만 아니라 약물 발견 및 개발을 가속화하기 위해 MOS(MicroOrganoSphere) 기술에 중점을 두고 있습니다.


모스란 무엇인가요?

Xilis의 독점 MicroOrganoSpher(MOS) 기술은 전체 미세 환경과 이질성을 포착하고 자동화되고 확장 가능한 솔루션을 제공하는 소형 환자 종양으로 구성됩니다. Xilis는 MOS 및 AI 기반 알고리즘을 사용하여 종양 전문의가 정보를 바탕으로 적시에 치료 결정을 내릴 수 있도록 병원을 위한 Xilis Response Score™를 개발하고 있습니다. 또한 MOS 기술은 실제 종양 미세 환경 분석, 높은 처리량의 전임상 모델링 및 임상 환자 선택 기능을 지원하여 항암제 개발 및 임상 시험 속도를 높이고 있습니다.


Mubadala Capital led the round.

The Duke Angel Network also participated.

LSP in Europe, Catalio Capital Management and previous nvestors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also joined the funding.

Shen, David Hsu and Hans Clevers founded the company. Clevers invented the “organoid” technology and also is a venture partner at LSP. Shen and Hsu teach at Duke University.

“Since my lab invented organoids a dozen years ago, we provided proof-of-concept for many applications, yet the technology remained slow, complex, and expensive,” Clevers said in a statement. ” Together with LSP, I have been looking for enabling technology to unlock the full potential, and Dr. Shen and Dr. Hsu’s invention of the MOS technology has torn down those hurdles and will accelerate its use both in the clinic and for drug discovery and development.”

The funds will be used “to further advance Xilis’ proprietary MOS technology, expand its AI-driven capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharma partners,” the company said.

“Genetic approaches to cancer diagnostics continue to be impactful, and Xilis is creating meaningful pathways for its Precision Oncology Platform to improve cancer care for a broader set of patients,” said Google Ventures (GV) Managing Partner Krishna Yeshwant. “Xilis brings together experts in the fields of organoid development and precision medicine, and I’m excited to work with this impressive team as they continue to develop a breakthrough approach.”

원본 출처: WRAL TechWire